Literature DB >> 31218405

Two cases of phenotypic switch of primary cutaneous T cell lymphoma after treatment with an aggressive course and review of the literature.

Etan Marks1, Yang Shi2, Yanhua Wang2.   

Abstract

A "phenotypic switch" (PS) is a well-known phenomenon that occurs in hematopoietic neoplasms, often after treatment. However, in cutaneous T cell lymphoma (CTCL), this event has rarely been reported, and thus, very little is known about its relevance to disease prognosis. We report two cases of patients that were diagnosed with a CD4+ mycosis fungoides with positive T cell receptor gene rearrangement studies. Both patients originally responded to treatment, but subsequently, their CTCL came back with a different phenotype of a CD4- CTCL. Gene rearrangement studies were performed on the second occurrence in order to prove that this was the same lymphoma. Both patients died from their CTCL. Additionally, we collected seven cases of primary CTCL from the literature with tissue samples from before and after treatment with molecular studies confirming these neoplasms contained the same T cell clone, providing evidence of a true PS. This too revealed a poor prognosis in the majority of these cases. CTCL should be worked up to determine whether a PS has occurred after therapy since it could confuse management of patients and appears to portend a poor prognosis.

Entities:  

Keywords:  Cutaneous T cell lymphoma; Mycosis fungoides; Phenotypic switch; Poor prognosis

Mesh:

Year:  2019        PMID: 31218405     DOI: 10.1007/s00428-019-02599-5

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  27 in total

Review 1.  Best practices in diagnostic immunohistochemistry: workup of cutaneous lymphoid lesions in the diagnosis of primary cutaneous lymphoma.

Authors:  Rajan Dewar; Aleodor Alexandru Andea; Joan Guitart; Daniel A Arber; Lawrence M Weiss
Journal:  Arch Pathol Lab Med       Date:  2015-03       Impact factor: 5.534

2.  Rapid onset of CD8+ aggressive T-cell lymphoma during bexarotene therapy in a patient with Sézary syndrome.

Authors:  Alexander Kreuter; Peter Altmeyer
Journal:  J Am Acad Dermatol       Date:  2005-12       Impact factor: 11.527

3.  Second malignancy after treatment of childhood acute myeloid leukemia.

Authors:  W Leung; R C Ribeiro; M Hudson; X Tong; D K Srivastava; J E Rubnitz; J T Sandlund; B I Razzouk; W E Evans; C H Pui
Journal:  Leukemia       Date:  2001-01       Impact factor: 11.528

4.  Immunophenotypic shift from CD4(+) to CD8(+) in mycosis fungoides.

Authors:  C Endo; Y Naka; T Miyagaki; H Fujita; M Sugaya; M Kawashima; Y Tsunemi
Journal:  Br J Dermatol       Date:  2016-07-27       Impact factor: 9.302

5.  Fatal Case of Primary Cutaneous Aggressive T-Cell Lymphoma Switching From a CD4+ to a CD8+ Phenotype: Progressive Disease With Bexarotene and Romidepsin Treatment.

Authors:  William T Johnson; Rebecca J Leeman-Neill; Parth Patel; Jonhan Ho; Lisa M Grandinetti; Jaroslaw Jedrych; Fiona E Craig
Journal:  Am J Dermatopathol       Date:  2016-11       Impact factor: 1.533

6.  Primary Cutaneous T-Cell Lymphomas Showing Gamma-Delta (γδ) Phenotype and Predominantly Epidermotropic Pattern are Clinicopathologically Distinct From Classic Primary Cutaneous γδ T-Cell Lymphomas.

Authors:  E Dean Merrill; Rose Agbay; Roberto N Miranda; Phyu P Aung; Michael T Tetzlaff; Ken H Young; Jonathan L Curry; Priyadharsini Nagarajan; Doina Ivan; Victor G Prieto; L Jeffrey Medeiros; Madeleine Duvic; Carlos A Torres-Cabala
Journal:  Am J Surg Pathol       Date:  2017-02       Impact factor: 6.394

7.  Histologic criteria for the diagnosis of mycosis fungoides: proposal for a grading system to standardize pathology reporting.

Authors:  J Guitart; J Kennedy; S Ronan; J S Chmiel; Y C Hsiegh; D Variakojis
Journal:  J Cutan Pathol       Date:  2001-04       Impact factor: 1.587

8.  Mycosis fungoides: report of the 2011 Society for Hematopathology/European Association for Haematopathology workshop.

Authors:  Sophie X Song; Rein Willemze; Steven H Swerdlow; Marsha C Kinney; Jonathan W Said
Journal:  Am J Clin Pathol       Date:  2013-04       Impact factor: 2.493

9.  A stable aberrant immunophenotype characterizes nearly all cases of cutaneous T-cell lymphoma in blood and can be used to monitor response to therapy.

Authors:  LaBaron T Washington; Yang O Huh; Linda C Powers; Madeleine Duvic; Dan Jones
Journal:  BMC Clin Pathol       Date:  2002-12-10

10.  Large granular lymphocyte leukemia and natural killer cell leukemia/lymphomas.

Authors:  Lubomir Sokol; Thomas P Loughran
Journal:  Curr Treat Options Oncol       Date:  2003-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.